NovaBridge Biosciences Unveils Promising Clinical Trial Data and Strategic Rebranding
08.11.2025 - 14:31:04 | boerse-global.de
Clinical-stage biopharmaceutical company NovaBridge Biosciences, formerly known as I-Mab, has released compelling updated Phase 1 data for its bispecific antibody candidate, givastomig. The complete dataset was presented in late October at the AACR-NCI-EORTC international conference, highlighting the drug’s performance in treating heavily pre-treated gastric cancer patients.
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, demonstrated an objective response rate of 18% in this challenging patient population. The disease control rate reached a notable 49%, with median progression-free survival recorded at 2.96 months and median overall survival at 7.49 months.
A significant finding from the trial reveals that treatment efficacy was consistent across various dose levels and CLDN18.2 expression thresholds. Researchers observed no new Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
